DS
ZNTL icon

DRW Securities’s Zentalis Pharmaceuticals ZNTL Stock Holding History

DRW Securities’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,830
Closed -$19.5K – 1674
2025
Q2 		$19.5K Buy
+16,830
New +$22.2K ﹤0.01% 1062

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DRW Securities's ZNTL Position: Q3 2025 in Review

DRW Securities sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 16,830 shares — an estimated $19.5K sold.

DRW Securities first reported a position in ZNTL in Q2 2025 and held it in 1 quarter. The position peaked at $19.5K in Q2 2025. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

  • DRW Securities reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • DRW Securities sold 16,830 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $19.5K.
  • DRW Securities first reported a position in Zentalis Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • DRW Securities's Zentalis Pharmaceuticals position peaked at $19.5K in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on DRW Securities's 13F filing for Q3 2025, filed 14 Nov 2025.